AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update

Journal of the American College of Cardiology

Volumn 58, Issue 23, 2011, Pages 2432-2446

  Smith Jr , Sidney C ^a   Benjamin, Emelia J ^a   Bonow, Robert O ^a   Braun, Lynne T ^a   Creager, Mark A ^a   Franklin, Barry A ^a   Gibbons, Raymond J ^a   Grundy, Scott M ^a   Hiratzka, Loren F ^a   Jones, Daniel W ^a   Lloyd Jones, Donald M ^a   Minissian, Margo ^a   Mosca, Lori ^a   Peterson, Eric D ^a   Sacco, Ralph L ^a   Spertus, John ^a   Stein, James H ^a   Taubert, Kathryn A ^a  

^a NONE

Author keywords

AHA Scientific Statements; coronary disease; risk factors; secondary prevention; vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; METFORMIN; METOPROLOL SUCCINATE; NICOTINIC ACID;

ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BARE METAL STENT; BLOOD PRESSURE REGULATION; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIET THERAPY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INDICATION; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFLUENZA; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; SURVIVAL RATE; SYSTOLIC DYSFUNCTION; TRANSIENT ISCHEMIC ATTACK; WEIGHT CONTROL;

AMERICAN HEART ASSOCIATION; ATHEROSCLEROSIS; BENCHMARKING; CARDIOLOGY; CORONARY ARTERY DISEASE; FOUNDATIONS; HUMANS; MORBIDITY; QUALITY OF HEALTH CARE; RISK REDUCTION BEHAVIOR; UNITED STATES; WORLD HEALTH;

EID: 81855224663     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.10.824     Document Type: Article

References (179)

1. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: [published correction appears in Circulation. 2006;113:e847] Circulation 113 2006 2363 2372 (Pubitemid 43947981)
2. S.F. Rothemich, S.H. Woolf, and R.E. Johnson Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study Ann Fam Med. 6 2008 60 68
3. A. Rosser, I. McDowvell, and C. Newvell Documenting smoking status: trial of three strategies Can Fam Physician 38 1992 1623 1628
4. U.S. Department of Health and Human Services Systems Change: Treating Tobacco Use and Dependence Based on the Public Health Service (PHS) Clinical Practice Guideline2008 Update www.ahrq.gov/clinic/tobacco/systems.htm Accessed September 25, 2011
5. S.R. Cummings, T.J. Coates, and R.J. Richard Training physicians in counseling about smoking cessation: a randomized trial of the "Quit for Life" program Ann Intern Med. 110 1989 640 647 (Pubitemid 19105113)
6. S.R. Cummings, R.J. Richard, and C.L. Duncan Training physicians about smoking cessation: a controlled trial in private practice J Gen Intern Med. 4 1989 482 489 (Pubitemid 20021981)
7. M.C. Fiore, C.R. Jaén, and T.B. Baker Treating Tobacco Use and Dependence: 2008 Update Clinical Practice Guideline May 2008 US Department of Health and Human Services, Public Health Service Rockville, MD http://www.surgeongeneral.gov/tobacco/treating-tobacco-use08.pdf Accessed December 9, 2010
8. C. Duncan, M.J. Stein, and S.R. Cummings Staff involvement and special follow-up time increase physicians counseling about smoking cessation: a controlled trial Am J Public Health 81 1991 899 901
9. N.R. Anthonisen, M.A. Skeans, R.A. Wise, J. Manfreda, R.E. Kanner, J.E. Connett Lung Health Study Research Group The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial Ann Intern Med. 142 2005 233 239 (Pubitemid 40216240)
10. U.S. Department of Health and Human Services The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report From the Surgeon General 2006 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health Atlanta, GA
11. Committee on Secondhand Smoke Exposure and Acute Coronary Events, Institute of Medicine Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence 2010 National Academies Press Washington, DC http://www.nap.edu/catalog/12649.html Accessed May 31, 2011
12. A.V. Chobanian, G.L. Bakris, H.R. Black National High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252 (Pubitemid 37553153)
13. L.J. Appel, T.J. Moore, and E. Obarzanek A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group N Engl J Med. 336 1997 1117 1124
14. F.M. Sacks, L.P. Svetkey, W.M. Vollmer DASH-Sodium Collaborative Research Group Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet N Engl J Med. 344 2001 3 10 (Pubitemid 32064838)
15. L.J. Appel, E.D. Frohlich, and J.E. Hall The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association Circulation 123 2011 1138 1143
16. S.P. Whelton, A. Chin, X. Xin, and J. He Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials Ann Intern Med. 136 2002 493 503 (Pubitemid 34252283)
17. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2004;291:2196 and JAMA. 2003;289:178] JAMA 288 2002 2981 2997
19. A.M. Dattilo, and P.M. Kris-Etherton Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr. 56 1992 320 328
20. S.A. Murphy, C.P. Cannon, S.D. Wiviott, C.H. McCabe, and E. Braunwald Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndrome: from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial J Am Coll Cardiol. 54 2009 2358 2362
21. H.N. Ginsberg, P. Kris-Etherton, and B. Dennis Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1 Arterioscler Thromb Vasc Biol. 18 1998 441 449 (Pubitemid 28125639)
22. E.J. Schaefer, S. Lamon-Fava, and L.M. Ausman Individual variability in lipoprotein cholesterol response to National Cholesterol Education Program Step 2 diets Am J Clin Nutr. 65 1997 823 830 (Pubitemid 27111091)
23. E.J. Schaefer, A.H. Lichtenstein, and S. Lamon-Fava Efficacy of a National Cholesterol Education Program Step 2 diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women Arterioscler Thromb Vasc Biol. 15 1995 1079 1085
24. S. Yu-Poth, G. Zhao, T. Etherton, M. Naglak, S. Jonnalagadda, and P.M. Kris-Etherton Effects of the National Cholesterol Education Programs Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis Am J Clin Nutr. 69 1999 632 646 (Pubitemid 29193386)
25. MRC/BHF Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
26. J.C. LaRosa, S.M. Grundy, D.D. Waters Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med. 352 2005 1425 1435 (Pubitemid 40471450)
27. T.R. Pedersen, O. Faergeman, J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [published correction appears in JAMA. 2005;294:3092] JAMA 294 2005 2437 2445 (Pubitemid 41627921)
28. C. Baigent, L. Blackwell, J. Emberson Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of more intense lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
29. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
30. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol. 53 2009 316 322
31. X.Q. Zhao, B.G. Brown, L. Hillger, D. Sacco, B. Bisson, L. Fisher, and J.J. Albers Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B Circulation 88 1993 2744 2753 (Pubitemid 23360201)
32. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med. 345 2001 1583 1592 (Pubitemid 33126837)
33. L. Campeau, D.B. Hunninghake, G.L. Knatterud Post CABG Trial Investigators Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors: NHLBI post coronary artery bypass graft clinical trial Circulation 99 1999 3241 3247 (Pubitemid 29293433)
34. H.B. Rubins, S.J. Robins, D. Collins Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med. 341 1999 410 418 (Pubitemid 29362514)
35. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol. 8 1986 1245 1255 (Pubitemid 17208898)
36. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease JAMA 251 1984 351 364
37. C.P. Cannon, E. Braunwald, C.H. McCabe Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354:778] N Engl J Med. 350 2004 1495 1504 (Pubitemid 38477774)
38. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol. 48 2006 438 445 (Pubitemid 44109954)
39. M.H. Frick, O. Elo, and K. Haapa Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med. 317 1987 1237 1245 (Pubitemid 17147964)
40. A. Keech, R.J. Simes, P. Barter FIELD Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published corrections appear in Lancet. 2006;368:1415 and Lancet. 2006;368:1420] Lancet 366 2005 1849 1861
41. S.J. Robins, H.B. Rubins, F.H. Faas Veterans Affairs HDL Intervention Trial (VA-HIT) Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT) Diabetes Care 26 2003 1513 1517 (Pubitemid 36929188)
42. J.C. LaRosa, S.M. Grundy, J.J. Kastelein, J.B. Kostis, H. Greten Treating to New Targets (TNT) Steering Committee and Investigators Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study) Am J Cardiol. 100 2007 747 752 (Pubitemid 47271930)
43. R.A. Hayward, H.M. Krumholz, D.M. Zulman, J.W. Timbie, and S. Vijan Optimizing statin treatment for primary prevention of coronary artery disease [published correction appears in Ann Intern Med. 2011;154:848] Ann Intern Med. 152 2010 69 77
44. P.M. Kris-Etherton, W.S. Harris, L.J. Appel Nutrition Committee Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [published correction appears in Circulation. 2003;107:512] Circulation 106 2002 2747 2757
45. H.C. Bucher, P. Hengstler, C. Schindler, and G. Meier N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials Am J Med. 112 2002 298 304 (Pubitemid 34219443)
46. L. Mosca, E.J. Benjamin, and K. Berra Effectiveness-based guidelines for the prevention of cardiovascular disease in women: 2011 update: a guideline from the American Heart Association [published correction appears in Circulation. 2011;123:e624] Circulation 123 2011 1243 1262
47. G.J. Balady, M.A. Williams, and P.A. Ades Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation Circulation 115 2007 2675 2682 (Pubitemid 46795281)
48. D.B. Mark, M.A. Hlatky, F.E. Harrell Jr, K.L. Lee, R.M. Califf, and D.B. Pryor Exercise treadmill score for predicting prognosis in coronary artery disease Ann Intern Med. 106 1987 793 800 (Pubitemid 17078969)
49. D.B. Mark, L. Shaw, and F.E. Harrell Jr. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease N Engl J Med. 325 1991 849 853
50. L. Vanhees, R. Fagard, L. Thijs, J. Staessen, and A. Amery Prognostic significance of peak exercise capacity in patients with coronary artery disease J Am Coll Cardiol. 23 1994 358 363 (Pubitemid 24049365)
51. T. Kavanagh, D.J. Mertens, L.F. Hamm, J. Beyene, J. Kennedy, P. Corey, and R.J. Shephard Prediction of long-term prognosis in 12,169 men referred for cardiac rehabilitation Circulation 106 2002 666 671 (Pubitemid 34851924)
52. T. Kavanagh, D.J. Mertens, and L.F. Hamm Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation J Am Coll Cardiol. 42 2003 2139 2143 (Pubitemid 37549899)
53. D.M. Lloyd-Jones, Y. Hong, and D. Labarthe Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Associations Strategic Impact Goal through 2020 and beyond Circulation 121 2010 586 613
54. U.S. Department of Health and Human Services 2008 Physical Activity Guidelines for Americans 2008 U.S. Department of Health and Human Services Washington, DC
55. R.S. Taylor, A. Brown, and S. Ebrahim Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials Am J Med. 116 2004 682 692 (Pubitemid 38581114)
56. T.H. Marwick, M.D. Hordern, T. Miller American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Nutrition, Physical Activity, and Metabolism; and the Interdisciplinary Council on Quality of Care and Outcomes Research Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 3244 3262
57. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) [published correction appears in Circulation. 2005;111:2013] Circulation 110 2004 588 636 (Pubitemid 39036178)
58. W.L. Haskell, I.M. Lee, and R.R. Pate Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association Circulation 116 2007 1081 1093 (Pubitemid 47329572)
59. M.A. Williams, W.L. Haskell, and P.A. Ades Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism Circulation 116 2007 572 584 (Pubitemid 47450265)
60. National Institutes of Health; National Heart, Lung, and Blood Institute 1998 National Institutes of Health, National Heart, Lung, and Blood Institute Bethesda, MD NIH publication No. 98-4083 http://www.nhlbi.nih.gov/guidelines/ obesity/ob-gdlns.pdf Accessed October 3, 2011
61. S. Klein, L.E. Burke, and G.A. Bray Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism Circulation 110 2004 2952 2967 (Pubitemid 39473623)
62. S.M. Grundy, J.I. Cleeman, and S.R. Daniels Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation. 2005;112:e297 and Circulation. 2005;112:e298] Circulation 112 2005 2735 2752 (Pubitemid 41532612)
63. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-evaluation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) [published corrections appear in Circulation. 2005;111:20134, Circulation. 2007;115:e411, and Circulation. 2010;121:441] Circulation 110 2004 e82 e292
64. R.J. Gibbons, J. Abrams, and K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) Circulation 107 2003 149 158 (Pubitemid 36070948)
65. E.E. Calle, M.J. Thun, J.M. Petrelli, C. Rodriguez, and C.W. Heath Jr. Body-mass index and mortality in a prospective cohort of U.S. adults N Engl J Med. 341 1999 1097 1105 (Pubitemid 29466221)
66. M.K. Jensen, S.E. Chiuve, and E.B. Rimm Obesity, behavioral lifestyle factors, and risk of acute coronary events Circulation 117 2008 3062 3069
67. J. Arnlöv, E. Ingelsson, J. Sundström, and L. Lind Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men Circulation 121 2010 230 236
68. C.J. Lavie, R.V. Milani, and H.O. Ventura Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss J Am Coll Cardiol. 53 2009 1925 1932
69. L. Gruberg, N.J. Weissman, and R. Waksman The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 39 2002 578 584 (Pubitemid 34158151)
70. E.J. Jacobs, C.C. Newton, and Y. Wang Waist circumference and all-cause mortality in a large U.S. cohort Arch Intern Med. 170 2010 1293 1301
71. J.S. Skyler, R. Bergenstal, and R.O. Bonow Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [published correction appears in Circulation. 2009;119:e605] Circulation 119 2009 351 357
72. T.N. Kelly, L.A. Bazzano, V.A. Fonseca, T.K. Thethi, K. Reynolds, and J. He Systematic review: glucose control and cardiovascular disease in type 2 diabetes Ann Intern Med. 151 2009 394 403
73. S. Kaul, A.F. Bolger, D. Herrington, R.P. Giugliano, and R.H. Eckel Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and the American College of Cardiology Foundation Circulation 121 2010 1868 1877
74. American Diabetes Association Standards of medical care in diabetes: 2011 Diabetes Care 34 Suppl 1 2011 S11 S61
75. E. Selvin, S. Bolen, and H.-C. Yeh Cardiovascular outcomes in trials of oral diabetes medications: a systematic review Arch Intern Med. 168 2008 2070 2080
76. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet.1998;352:1558] Lancet 352 1998 854 865
77. F.M. Turnbull, C. Abraira, R.J. Anderson Control Group Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia. 2009;52:2470] Diabetologia 52 2009 2288 2298
78. K.K. Ray, S.R. Seshasai, and S. Wijesuriya Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Lancet 373 2009 1765 1772
79. 1c in people with type 2 diabetes: a retrospective cohort study Lancet 375 2010 481 489
80. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med. 359 2008 1577 1589
81. R.C. Becker, T.W. Meade, P.B. Berger American College of Chest Physicians The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 776S 814S (Pubitemid 351894917)
82. C. Baigent, L. Blackwell, R. Collins Antithrombotic Trialists (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
83. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and N Engl J Med. 2001;345:1716] N Engl J Med. 345 2001 494 502 (Pubitemid 32758501)
84. S.R. Mehta, S. Yusuf, R.J. Peters Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533 (Pubitemid 32772726)
85. S.R. Steinhubl, P.B. Berger, J.T. Mann 3rd CREDO Investigators Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289:987] JAMA 288 2002 2411 2420 (Pubitemid 35340537)
86. G. Montalescot, S.D. Wiviott, E. Braunwald TRITON-TIMI 38 Investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
87. J.H. Chesebro, V. Fuster, and L.R. Elveback Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations N Engl J Med. 310 1984 209 214 (Pubitemid 14221958)
88. R.L. Lorenz, C.V. Schacky, and M. Weber Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation Lancet 1 1984 1261 1264 (Pubitemid 14111081)
89. G.V. Sharma, S.F. Khuri, M. Josa, E.D. Folland, and A.F. Parisi The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency Circulation 68 1983 II218 II221
90. D.T. Mangano Multicenter Study of Perioperative Ischemia Research Group Aspirin and mortality from coronary bypass surgery N Engl J Med. 347 2002 1309 1317 (Pubitemid 35215321)
91. P.H. Halkes, J. van Gijn, L.J. Kappelle, P.J. Koudstaal, A. Algra The ESPRIT Study Group Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial [published correction appears in Lancet 2007;369:274] Lancet 367 2006 1665 1673
92. M. Catalano, G. Born, R. Peto Critical Leg Ischaemia Prevention Study (CLIPS) Group Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial J Intern Med. 261 2007 276 284
93. S.S. Anand, and S. Yusuf Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis [published correction appears in JAMA. 2000;284:45] JAMA 282 1999 2058 2067
94. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, aspirin, or both after myocardial infarction N Engl J Med. 347 2002 969 974
95. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254] Arch Intern Med. 154 1994 1449 1457
96. R.O. Bonow, B.A. Carabello, and C. Kanu ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) [published corrections appear in Circulation. 2010;121:e443 and Circulation. 2007;115:e409] Circulation 114 2006 e84 e231
97. L.D. Fiore, M.D. Ezekowitz, M.T. Brophy, D. Lu, J. Sacco, P. Peduzzi Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study Circulation 105 2002 557 563 (Pubitemid 34123428)
98. S.S. Anand, and S. Yusuf Oral anticoagulants in patients with coronary artery disease J Am Coll Cardiol. 41 Suppl S 2003 62S 69S (Pubitemid 36223349)
99. A.G. Turpie, M. Gent, and A. Laupacis A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement N Engl J Med. 329 1993 524 529 (Pubitemid 23232620)
100. C.K. Mok, J. Boey, and R. Wang Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial Circulation 72 1985 1059 1063 (Pubitemid 16205407)
101. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial Lancet 348 1996 633 638
102. C. Kearon, M. Gent, and J. Hirsh A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [published correction appears in N Engl J Med. 1999;341:298] N Engl J Med. 340 1999 901 907 (Pubitemid 29141050)
103. R.J. Adams, G. Albers, and M.J. Alberts Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack [published correction appears in Stroke. 2010;41:e455] Stroke 39 2008 1647 1652
104. R.L. Sacco, H.C. Diener, S. Yusuf PRoFESS Study Group Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke N Engl J Med. 359 2008 1238 1251
105. J.P. Mohr, J.L. Thompson, R.M. Lazar Warfarin-Aspirin Recurrent Stroke Study Group A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke N Engl J Med. 345 2001 1444 1451
106. P.H. Halkes, J. van Gijn, L.J. Kappelle, P.J. Koudstaal, A. Algra ESPRIT Study Group Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial Lancet Neurol. 6 2007 115 124 (Pubitemid 46097527)
107. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) Circulation 113 2006 e463 e654
108. J.S. Berger, M.J. Krantz, J.M. Kittelson, and W.R. Hiatt Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials JAMA 301 2009 1909 1919
109. F.G. Fowkes, J.F. Price, M.C. Stewart Aspirin for Asymptomatic Atherosclerosis Trialists Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848
110. S. Anand, S. Yusuf, C. Xie Warfarin Antiplatelet Vascular Evaluation Trial Investigators Oral anticoagulant and antiplatelet therapy and peripheral arterial disease N Engl J Med. 357 2007 217 227 (Pubitemid 47080386)
111. D.L. Bhatt, K.A. Fox, W. Hacke CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med. 354 2006 1706 1717
112. D.L. Bhatt, M.D. Flather, W. Hacke CHARISMA Investigators Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol. 49 2007 1982 1988 (Pubitemid 46694290)
113. S.D. Wiviott, E. Braunwald, C.H. McCabe TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 357 2007 2001 2015 (Pubitemid 350106708)
114. L. Wallentin, R.C. Becker, A. Budaj PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 361 2009 1045 1057
115. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med. 360 2009 354 362
116. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141] BMJ 324 2002 71 86
117. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
118. Z.M. Chen, L.X. Jiang, Y.P. Chen COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
119. S.S. Brar, J. Kim, and S.K. Brar Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions J Am Coll Cardiol. 51 2008 2220 2227 (Pubitemid 351754993)
120. C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 Suppl 2008 199S 233S (Pubitemid 351894914)
121. S.R. Steinhubl, D.L. Bhatt, D.M. Brennan CHARISMA Investigators Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding Ann Intern Med. 150 2009 379 386
122. V.L. Serebruany, S.R. Steinhubl, and P.B. Berger Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials Am J Cardiol. 95 2005 1218 1222 (Pubitemid 40616424)
123. K.L. Furie, S.E. Kasner, R.J. Adams American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 227 276
124. R. Garg, S. Yusuf Collaborative Group on ACE Inhibitor Trials Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [published correction appears in JAMA. 1995;274:462] JAMA 273 1995 1450 1456
125. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med. 2000;342:1376 and N Engl J Med. 2000;342:748] N Engl J Med. 342 2000 145 153
126. K.M. Fox EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788 (Pubitemid 37093919)
127. E. Braunwald, M.J. Domanski, S.E. Fowler PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med. 351 2004 2058 2068
128. F. Turnbull, B. Neal, C. Algert Blood Pressure Lowering Treatment Trialists Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials Arch Intern Med. 165 2005 1410 1419 (Pubitemid 40973424)
129. R. Kunz, C. Friedrich, M. Wolbers, and J.F. Mann Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med. 148 2008 30 48 (Pubitemid 351688350)
130. B. Pitt, P.A. Poole-Wilson, and R. Segal Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study (ELITE II) Lancet 355 2000 1582 1587 (Pubitemid 30240502)
131. M.A. Pfeffer, K. Swedberg, C.B. Granger CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [published correction appears in Lancet 2009;374:1744] Lancet 362 2003 759 766 (Pubitemid 37093915)
132. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction appears in N Engl J Med. 2004;350:203] N Engl J Med. 349 2003 1893 1906
133. S. Yusuf, K. Teo, and C. Anderson Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANCEND) Investigators. Effects of angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial [published correction appears in Lancet 2008;372:1384] Lancet 372 2008 1174 1183
134. S. Yusuf, K.K. Teo, J. Pogue ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med. 358 2008 1547 1559 (Pubitemid 351522739)
135. D.B. Matchar, D.C. McCrory, and L.A. Orlando Systematic review: comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers for treating essential hypertension Ann Intern Med. 148 2008 16 29 (Pubitemid 351664943)
136. B. Pitt, W. Remme, F. Zannad Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348:2271] N Engl J Med. 348 2003 1309 1321 (Pubitemid 36384098)
137. F. Zannad, J.J.V. McMurray, H. Krum EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
138. M. Packer, M.R. Bristow, J.N. Cohn U.S. Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure N Engl J Med. 334 1996 1349 1355 (Pubitemid 26152713)
139. N. Freemantle, J. Cleland, P. Young, J. Mason, and J. Harrison β Blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737 (Pubitemid 29290470)
140. P.A. Poole-Wilson, K. Swedberg, J.G. Cleland COMET Investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13 (Pubitemid 36835815)
141. M.J. Domanski, H. Krause-Steinrauf, and B.M. Massie A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS J Card Fail 9 2003 354 363 (Pubitemid 37351802)
142. O.R. de Peuter, F. Lussana, R.J.G. Peters, H.R. Bller, and P.W. Kamphuisen A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure Neth J Med. 67 2009 284 294
143. L.G. De Lima, B. Soares, H. Saconato, E.M.K. da Silva, and.N. Atallah Beta blockers for preventing stroke recurrence (Protocol) Cochrane Database Syst Rev. 3 2009 10.1002/14651858 CD007890 http://onlinelibrary.wiley.com/doi/10. 1002/14651858.CD007890/abstract CD007890. Accessed September 22, 2011
144. E.P. Gurfinkel, R. Leon de la Fuente, O. Mendiz, and B. Mautner Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study Eur Heart J. 25 2004 25 31 (Pubitemid 38055589)
145. A. Ciszewski, Z.T. Bilinska, and L.B. Brydak Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study Eur Heart J. 29 2008 1350 1358 (Pubitemid 351806477)
146. M.M. Davis, K. Taubert, and A.L. Benin Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology [published correction appears in Circulation. 2006;114:e616] Circulation 114 2006 1549 1553 (Pubitemid 44527011)
147. Centers for Disease Control and Prevention Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 MMWR Morb Mortal Wkly Rep. 59 2010 1 62
148. R.C. Ziegelstein, B.D. Thombs, J.C. Coyne, and P. de Jonge Routine screening for depression in patients with coronary heart disease: never mind J Am Coll Cardiol. 54 2009 886 890
149. B.D. Thombs, P. de Jonge, and J.C. Coyne Depression screening and patient outcomes in cardiovascular care: a systematic review JAMA 300 2008 2161 2171
150. U.S. Preventive Services Task Force Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement Ann Intern Med. 151 2009 784 792
151. B.L. Rollman, B.H. Belnap, and M.S. LeMenager Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial JAMA 302 2009 2095 2103
152. K.K. Larsen, E. Agerbo, B. Christensen, J. Sondergaard, and M. Vestergaard Myocardial infarction and risk of suicide: a population-based case-control study Circulation 122 2010 2388 2393
153. R.S. Taylor, H. Dalal, K. Jolly, T. Moxham, and A. Zawada Home-based versus centre-based cardiac rehabilitation Cochrane Database Syst Rev. 1 2010 CD007130 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007130.pub2/full doi:1002/14651858.CD007130.pub2. Accessed September 22, 2011
154. A.M. Clark, L. Hartling, B. Vandermeer, and F.A. McAlister Meta-analysis: secondary prevention programs for patients with coronary artery disease Ann Intern Med. 143 2005 659 672
155. R. Hambrecht, C. Walther, and S. Mobius-Winkler Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial Circulation 109 2004 1371 1378 (Pubitemid 38387823)
156. B.G. Hammill, L.H. Curtis, K.A. Schulman, and D.J. Whellan Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries Circulation 121 2010 63 70
157. A.S. Leon, B.A. Franklin, and F. Costa Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) [published correction appears in Circulation. 2005;111:1717] Circulation 111 2005 369 376
158. M. McDermott, P. Ades, and J.M. Guralnik Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial JAMA 301 2009 165 174
159. C.M. OConnor, D.J. Whellan, K.L. Lee HF-ACTION Investigators Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial JAMA 301 2009 1439 1450
160. R. Belardinelli, D. Georgiou, G. Cianci, and A. Purcaro Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome Circulation 99 1999 1173 1182 (Pubitemid 29120089)
161. ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. doi:10.1136/bmj.37938. 645220.EE (published 16 January 2004).
162. C. Passino, S. Severino, R. Poletti, M.F. Piepoli, C. Mammini, A. Clerico, A. Gabutti, G. Nassi, and M. Emdin Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure J Am Coll Cardiol. 47 2006 1835 1839
163. A.M. Clark, M. Haykowsky, and J. Kryworuchko A meta-analysis of randomized control trials of home-based secondary prevention programs for coronary artery disease Eur J Cardiovasc Prev Rehabil. 17 2010 261 270
164. R.J. Thomas, M. King, K. Lui, N. Oldridge, I.L. Pia, and J. Spertus AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services Circulation 116 2007 1611 1642 (Pubitemid 47511427)
165. P.D. Thompson, D. Buchner, and I.L. Pina Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation 107 2003 3109 3116 (Pubitemid 36758987)
166. C. Walther, S. Möbius-Winkler, and A. Linke Regular exercise training compared with percutaneous intervention leads to a reduction of inflammatory markers and cardiovascular events in patients with coronary artery disease Eur J Cardiovasc Prev Rehabil. 15 2008 107 112 (Pubitemid 351263264)
167. L. Watson, B. Ellis, and G.C. Leng Exercise for intermittent claudication Cochrane Database Syst Rev. 4 2008 CD000990
168. N.K. Wenger, E.S. Froelicher, and P.A. Ades Cardiac Rehabilitation: Clinical Practice Guideline 17 1995 U.S. Department of Health & Human Services Washington, DC AHCPR publication No. 96-0672
169. C.P. Cannon, E. Braunwald, C.H. McCabe Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006;354:778] N Engl J Med. 350 2004 1495 1504 (Pubitemid 38477774)
170. J. Shepherd, G.J. Blauw, M.B. Murphy PROSPER Study Group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
171. P.S. Sever, B. Dahlöf, N.R. Poulter ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
172. S.M. Grundy, J.I. Cleeman, C.N. Merz Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763] Circulation 110 2004 227 239 (Pubitemid 38924592)
173. V.L. Roger, A.S. Go, D.M. Lloyd-Jones American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics2011 update: a report from the American Heart Association [published correction appears in Circulation. 2011;123:e240] Circulation 123 2011 e18 e209
174. American Heart Association Web site Focus on quality http://www.heart. org/HEARTORG/HealthcareProfessional/GetWithTheGuidelinesHFStroke/ Focus-on-Quality-Home-Page-UCM-306348-SubHomePage.jsp Accessed July 14, 2011
175. AHA/ADA/ACS The Guideline Advantage Program http://www. theguidelineadvantage.org Accessed July 14, 2011
176. PINNACLE Registry http://www.pinnacleregistry.org Accessed July 14, 2011
177. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 2011 In press
178. T.W. Rooke, A.T. Hirsch, and S. Misra 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 124 2011 2020 2045
179. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) Circulation 113 2006 1474 1547